Kirin Q2 FY2026: Soaring Profits, Upward Revision, and Jamieson Acquisition

Kirin's second-quarter results showed significant revenue and profit growth across all business segments, boosted by asset sales. Revenue rose 7.2% year on year to ¥1,217.8 billion, with price hikes and premiumization in the core alcohol beverages segment and contributions from all other units. Business profit surged 36.1% to ¥128.3 billion, helped by the full-year consolidation of Fancl and a strong recovery in on-trade alcohol sales and pharmaceuticals. Net profit attributable to owners of the parent nearly doubled, up 92.5% to ¥101.7 billion, after booking a ¥29.0 billion gain on the sale of the Four Roses bourbon brand, which lifted operating profit to ¥129.0 billion, up 87.8%.

The weaker yen provided a tailwind, inflating overseas earnings when translated back into yen. Domestic beer sales, led by Kirin Ichiban Shibori, rebounded, and on-trade demand was brisk ahead of an October liquor tax reform. While raw material and logistics costs continued to rise, price pass-through and cost reduction measures cushioned the impact.

All four reportable segments increased profits, with the strongest growth coming from pharmaceuticals.

Alcohol Beverages revenue reached ¥517.8 billion (+5.1%) and segment profit rose 16.8% to ¥62.0 billion, driven by domestic beer and ready-to-drink products as well as improved on-trade channels in Australia. Non-Alcohol Beverages saw revenue climb 8.5% to ¥294.8 billion, while profit edged up 4.8% to ¥30.9 billion, supported by strong sales of Kirin Gogo no Kocha and Tropicana in Japan and volume gains in the US Coca-Cola bottling business.

Pharmaceuticals delivered a standout performance, with revenue up 14.3% to ¥263.4 billion and profit soaring 80.7% to ¥60.5 billion, fueled by global expansion of Kyowa Kirin’s key drugs such as Crysvita and Poteligeo and higher royalty income. The Health Science segment, including Fancl and Blackmores, posted revenue of ¥128.8 billion (+1.3%) and profit of ¥10.4 billion (+20.8%), reflecting the full-year impact of the Fancl consolidation and a gradual recovery in cross-border e-commerce to China.

Total assets at the end of the half stood at ¥3,401.2 billion, down 2.7% from the prior year-end, reflecting portfolio restructuring and debt reduction. Cash and equivalents rose 34.1% to ¥168.0 billion, while interest-bearing debt declined by about ¥40 billion to ¥843.6 billion, pushing the equity ratio up to 40.0% from 36.8%.

Operating cash flow surged to ¥137.3 billion, more than double the prior year, and investing activities generated a ¥53.6 billion inflow, boosted by the ¥114.4 billion proceeds from the Four Roses sale. These funds were partly used for a ¥34.5 billion share buyback, ¥29.9 billion in dividend payments, and ¥40.0 billion in bond redemptions, resulting in net financing outflows of ¥162.4 billion.

The company raised the interim dividend to ¥38 per share (from ¥37) and plans a full-year dividend of ¥76, up ¥2 from the previous year. It also retired 236.57 million treasury shares, reducing the total outstanding to 816 million, underscoring a commitment to shareholder returns and capital efficiency.

The earnings report flagged several risk factors:

• Currency fluctuations, with a higher yen potentially eroding overseas earnings.
• Elevated raw material and energy costs, particularly for malt and aluminum cans, which could pressure margins.
• The impact of a planned liquor tax consolidation in October 2026 that may intensify price competition.
• Integration risks from large acquisitions like Fancl and the newly announced Jamieson Wellness deal, with the latter carrying a ¥218.3 billion price tag and potential goodwill impairment.
• Pharmaceutical development risks, including pipeline progress and regulatory changes.
• Geopolitical risks in key markets such as China and Australia that could dampen overseas performance.

Kirin raised its full-year forecasts, now projecting revenue of ¥2,480.0 billion (+1.9% YoY), business profit of ¥253.0 billion (+0.5%), operating profit of ¥230.0 billion (+9.7%), and net profit of ¥160.0 billion (+8.4%). The revised outlook assumes exchange rates of ¥145 per US dollar and ¥95 per Australian dollar. The upgrade reflects the strong first-half momentum, the inclusion of the Four Roses gain, and continued robust demand in alcohol and pharmaceuticals. The pharmaceutical unit is expected to benefit further from Crysvita’s global sales growth and new drug contributions. The full-year dividend forecast was maintained at ¥76 per share.

Kirin executed significant portfolio moves during the half. In April 2026, its US subsidiary sold the Four Roses bourbon brand to E.&J. Gallo Winery, generating a ¥29.0 billion gain and total proceeds of approximately ¥114.4 billion, including the collection of subsidiary loans. The sale sharpens Kirin’s focus on higher-return brands.

On August 7, the company announced a deal to acquire Canadian-listed Jamieson Wellness for about ¥218.3 billion (C$1.9 billion), with closing expected in October 2026. Jamieson is a leading North American vitamins, minerals, and supplements (VMS) brand, and the acquisition is a cornerstone of Kirin’s global health science expansion, following the takeovers of Fancl and Blackmores.